← All Surrozen, Inc/de filings

Surrozen, Inc/de 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SRZN
Surrozen, Inc/de
10-K: Surrozen Reports Increased Losses, Advances Ophthalmology Pipeline
Surrozen, Inc. reported a significant increase in net losses for 2025, driven by non-cash charges and increased R&D, while advancing its Wnt-pathway ophthalmology pipeline and securing new financing.
NASDAQ
SRZN
Surrozen, Inc/de
10-K: Surrozen, Inc. Reports 2024 Financial Results and Provides Business Update
Surrozen, Inc.'s 10-K filing reveals a year of strategic shifts, pipeline advancements, and financial recalibration as the company focuses on ophthalmology and navigates ongoing losses.
NASDAQ
SRZN
Surrozen, Inc/de
10-K: Surrozen Inc. Files 10-K Report, Highlights Progress in Wnt Pathway Therapeutics
Surrozen Inc.'s 10-K filing details the company's financial status, clinical trial progress, and strategic focus on Wnt pathway modulation for tissue repair.